Ranbaxy, GSK Settle Patent Dispute Over Imitrex (India)
This article was originally published in PharmAsia News
Executive Summary
Ranbaxy Laboratories and GlaxoSmithKline settled a patent dispute over Ranbaxy's generic version of Imitrex (sumatriptan) for treating migraines. The agreement calls for India's Ranbaxy to be able to sell its generic in the U.S. after next December. Other parts of the settlement were not disclosed, but Ranbaxy estimates annual Imitrex sales at $985 million. (Click here for more
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.